Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas.

about

Phosphorylated epidermal growth factor receptor expression and KRAS mutation status in salivary gland carcinomas.

Item

http://www.wikidata.org/entity/Q40657619

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Phosphorylated epidermal growt ...... in salivary gland carcinomas.

@en

type

Item

label

Phosphorylated epidermal growt ...... in salivary gland carcinomas.

@en

prefLabel

Phosphorylated epidermal growt ...... in salivary gland carcinomas.

@en

P1476

Phosphorylated epidermal growt ...... s in salivary gland carcinomas

@en

P2093

A C Kübler

http://www.w3.org/2001/XMLSchema#string

A Rosenwald

http://www.w3.org/2001/XMLSchema#string

A Strehl

http://www.w3.org/2001/XMLSchema#string

C Linz

http://www.w3.org/2001/XMLSchema#string

F Beckford

http://www.w3.org/2001/XMLSchema#string

R Brands

http://www.w3.org/2001/XMLSchema#string

T Schneider

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer.

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Hyperactive Ras in developmental disorders and cancer

EGFR antagonists in cancer treatment

P304

541-551

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00784-015-1541-1

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Urs Müller-richter

S Hartmann

P577

2015-08-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26245271

http://www.w3.org/2001/XMLSchema#string

P921

phosphorylation